FierceBiotech 31 mai 2026 ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
FierceBiotech 30 mai 2026 In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
FierceBiotech 30 mai 2026 ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
FierceBiotech 29 mai 2026 Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
FierceBiotech 29 mai 2026 AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
FierceBiotech 29 mai 2026 Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
FierceBiotech 29 mai 2026 ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
FierceBiotech 29 mai 2026 ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger
FierceBiotech 29 mai 2026 Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field
FierceBiotech 29 mai 2026 Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
FierceBiotech 28 mai 2026 Icon ends internal accounting investigation, finds it overstated revenue in prior years
FierceBiotech 28 mai 2026 FDA extends Beren’s rare disease review after info request, further stretching saga
FierceBiotech 28 mai 2026 Human Longevity launches newco, teams with Insilico for AI-powered longevity research
FierceBiotech 28 mai 2026 Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals
FierceBiotech 28 mai 2026 GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease